| Autor: |
Szewczyk, Kamila, Szewczyk, Bartłomiej, Krzesłowska, Wiktoria Julia, Pytel, Paulina, Wiśniewski, Szymon, Hołownia, Weronika |
| Předmět: |
|
| Zdroj: |
Journal of Education, Health & Sport; Dec2024, Vol. 74, p1-18, 18p |
| Abstrakt: |
Introduction: Severe asthma is a chronic respiratory condition that affects a significant number of individuals, causing persistent inflammation of the airways and leading to recurrent symptoms such as wheezing, coughing, and shortness of breath. While conventional asthma treatments, including inhaled corticosteroids and bronchodilators, are generally effective for most asthma patients, they may not always provide sufficient relief for individuals with severe asthma. In such cases, the use of biologic agents licensed specifically for severe asthma can be a valuable treatment option. Aim of the study: This article aims to explore the different biologic agents licensed for severe asthma and delve into their effectiveness in managing this complex and challenging condition. Material and methods: Literature available in the PubMed database was reviewed using the following keywords: biologic agents for asthma; omalizumab; mepolizumab; bernalizumab; tezepelumab; monoclonal antibodies. Conclusions: These medications are designed to target the underlying mechanisms of severe asthma, addressing the root causes of the condition rather than just managing the symptoms. As a result, they have shown promising results in improving symptoms and reducing exacerbations in individuals with severe asthma. By understanding the potential benefits of these medications, healthcare professionals can make informed decisions when it comes to treating patients with severe asthma. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
